• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.

作者信息

Kizhakeyil Atish, Zaini Nurmahirah Binte Mohammed, Poh Zhi Sheng, Wong Brandon Han Siang, Loh Xinpeng, Ng Aik Seng, Low Zun Siong, Prasannan Praseetha, Gong Chun, Tan Michelle Guet Khim, Nagarajan Chandramouli, Huang Dachuan, Lu Pang Wan, Lim Jing Quan, Barrans Sharon, Ong Choon Kiat, Lim Soon Thye, Chng Wee Joo, Follows George, Hodson Daniel J, Du Ming Qing, Goh Yeow Tee, Tan Suat Hoon, Grigoropoulos Nicholas Francis, Verma Navin Kumar

机构信息

Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, 11 Mandalay Road, Clinical Sciences Building, Singapore, 308232, Singapore.

Department of Haematology, Singapore General Hospital, The Academia, Level 3, 20 College Road, Singapore, 169856, Singapore.

出版信息

Mol Cancer. 2021 Oct 16;20(1):134. doi: 10.1186/s12943-021-01437-0.

DOI:10.1186/s12943-021-01437-0
PMID:34654425
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8520256/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e0/8520256/55d7c5e460dd/12943_2021_1437_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e0/8520256/f0dcdea7bfcb/12943_2021_1437_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e0/8520256/55d7c5e460dd/12943_2021_1437_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e0/8520256/f0dcdea7bfcb/12943_2021_1437_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23e0/8520256/55d7c5e460dd/12943_2021_1437_Fig2_HTML.jpg

相似文献

1
DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes.DDX3X缺失是弥漫性大B细胞淋巴瘤的不良预后标志物，且与侵袭性非霍奇金淋巴瘤亚型的化疗耐药相关。
Mol Cancer. 2021 Oct 16;20(1):134. doi: 10.1186/s12943-021-01437-0.
2
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.磷酸化STAT3表达在原发性弥漫性大B细胞淋巴瘤中的临床意义
Clin Cancer Res. 2014 Oct 1;20(19):5113-23. doi: 10.1158/1078-0432.CCR-14-0683. Epub 2014 Aug 14.
3
Determination of cyclin D1 and CD20 mRNA levels by real-time quantitative RT-PCR from archival tissue sections of mantle cell lymphoma and other non-Hodgkin's lymphomas.通过实时定量逆转录聚合酶链反应，从套细胞淋巴瘤和其他非霍奇金淋巴瘤的存档组织切片中测定细胞周期蛋白D1和CD20信使核糖核酸水平。
J Mol Diagn. 2002 Nov;4(4):201-8. doi: 10.1016/S1525-1578(10)60704-0.
4
Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).bcl-2蛋白表达在侵袭性非霍奇金淋巴瘤中的预后意义。成人淋巴瘤研究组（GELA）。
Blood. 1996 Jan 1;87(1):265-72.
5
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.DYRK2基因沉默可增加非霍奇金淋巴瘤细胞的增殖，但可逆转其多药耐药性。
Int J Biol Macromol. 2015 Nov;81:809-17. doi: 10.1016/j.ijbiomac.2015.08.067. Epub 2015 Sep 2.
6
Frequent alteration of MDM2 and p53 in the molecular progression of recurring non-Hodgkin's lymphoma.复发性非霍奇金淋巴瘤分子进展中MDM2和p53的频繁改变。
Histopathology. 2002 Oct;41(4):322-30. doi: 10.1046/j.1365-2559.2002.01506.x.
7
Inhibition of demethylase KDM6B sensitizes diffuse large B-cell lymphoma to chemotherapeutic drugs.去甲基化酶KDM6B的抑制使弥漫性大B细胞淋巴瘤对化疗药物敏感。
Haematologica. 2017 Feb;102(2):373-380. doi: 10.3324/haematol.2016.144964. Epub 2016 Oct 14.
8
ALDH1A1 mediates resistance of diffuse large B cell lymphoma to the CHOP regimen.醛脱氢酶1家族成员A1（ALDH1A1）介导弥漫性大B细胞淋巴瘤对CHOP方案的耐药性。
Tumour Biol. 2014 Dec;35(12):11809-17. doi: 10.1007/s13277-014-2335-9. Epub 2014 Oct 25.
9
Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance.外泌体衍生的 miRNA 作为弥漫性大 B 细胞淋巴瘤化疗耐药的预测性生物标志物。
Epigenomics. 2019 Jan;11(1):35-51. doi: 10.2217/epi-2018-0123. Epub 2018 Sep 13.
10
Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.来那度胺在活化 B 细胞样亚型弥漫性大 B 细胞淋巴瘤中的疗效依赖于 IRF4 和 cereblon 的表达。
Br J Haematol. 2013 Feb;160(4):487-502. doi: 10.1111/bjh.12172. Epub 2012 Dec 18.

引用本文的文献

1
An helicase reporter system for quantifying DDX3X and DDX3Y activities.一种用于量化DDX3X和DDX3Y活性的解旋酶报告系统。
Bioeng Transl Med. 2025 Apr 18;10(3):e10720. doi: 10.1002/btm2.10720. eCollection 2025 May.
2
Diagnostic Power of MicroRNAs in Melanoma: Integrating Machine Learning for Enhanced Accuracy and Pathway Analysis.微小RNA在黑色素瘤中的诊断能力：整合机器学习以提高准确性和通路分析
J Cell Mol Med. 2025 Jan;29(2):e70367. doi: 10.1111/jcmm.70367.
3
Proteome analysis of CD5-positive diffuse large B cell lymphoma FFPE tissue reveals downregulation of DDX3X, DNAJB1, and B cell receptor signaling pathway proteins including BTK and Immunoglobulins.

本文引用的文献

1
Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis.RNA 解旋酶 DDX3X 和 DDX3Y 的顺序反向失调促进 MYC 驱动的淋巴瘤发生。
Mol Cell. 2021 Oct 7;81(19):4059-4075.e11. doi: 10.1016/j.molcel.2021.07.041. Epub 2021 Aug 25.
2
DDX3X: structure, physiologic functions and cancer.DDX3X：结构、生理功能与癌症。
Mol Cancer. 2021 Feb 24;20(1):38. doi: 10.1186/s12943-021-01325-7.
3
Genetic and epigenetic determinants of diffuse large B-cell lymphoma.弥漫性大 B 细胞淋巴瘤的遗传和表观遗传决定因素。
CD5阳性弥漫性大B细胞淋巴瘤福尔马林固定石蜡包埋组织的蛋白质组分析显示DDX3X、DNAJB1以及包括BTK和免疫球蛋白在内的B细胞受体信号通路蛋白表达下调。
Clin Proteomics. 2023 Sep 13;20(1):36. doi: 10.1186/s12014-023-09422-z.
4
The Viral Protein K7 Inhibits Biochemical Activities and Condensate Formation by the DEAD-box Helicase DDX3X.病毒蛋白 K7 抑制 DEAD-box 解旋酶 DDX3X 的生化活性和凝聚物形成。
J Mol Biol. 2023 Oct 1;435(19):168217. doi: 10.1016/j.jmb.2023.168217. Epub 2023 Jul 28.
5
The RNA helicase DDX3 and its role in c-MYC driven germinal center-derived B-cell lymphoma.RNA解旋酶DDX3及其在c-MYC驱动的生发中心来源的B细胞淋巴瘤中的作用。
Front Oncol. 2023 Mar 24;13:1148936. doi: 10.3389/fonc.2023.1148936. eCollection 2023.
6
Characteristics and prognosis of rrDLBCL with TP53 mutations and a high-risk subgroup represented by the co-mutations of DDX3X-TP53.携带 TP53 突变和 DDX3X-TP53 共突变的高危亚组 rrDLBCL 的特征和预后。
Cancer Med. 2023 May;12(9):10267-10279. doi: 10.1002/cam4.5756. Epub 2023 Mar 27.
7
DEAD-Box RNA Helicases DDX3X and DDX5 as Oncogenes or Oncosuppressors: A Network Perspective.DEAD盒RNA解旋酶DDX3X和DDX5作为癌基因或抑癌基因：网络视角
Cancers (Basel). 2022 Aug 6;14(15):3820. doi: 10.3390/cancers14153820.
8
A Dual Role of DDX3X in dsRNA-Derived Innate Immune Signaling.DDX3X在双链RNA衍生的固有免疫信号传导中的双重作用。
Front Mol Biosci. 2022 Jul 6;9:912727. doi: 10.3389/fmolb.2022.912727. eCollection 2022.
Blood Cancer J. 2020 Dec 4;10(12):123. doi: 10.1038/s41408-020-00389-w.
4
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
5
The crosstalk between STAT3 and p53/RAS signaling controls cancer cell metastasis and cisplatin resistance via the Slug/MAPK/PI3K/AKT-mediated regulation of EMT and autophagy.STAT3与p53/RAS信号之间的相互作用通过Slug/MAPK/PI3K/AKT介导的EMT和自噬调节来控制癌细胞转移和顺铂耐药性。
Oncogenesis. 2019 Oct 9;8(10):59. doi: 10.1038/s41389-019-0165-8.
6
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.NCCN 指南解读：B 细胞淋巴瘤，第 3.2019 版。
J Natl Compr Canc Netw. 2019 Jun 1;17(6):650-661. doi: 10.6004/jnccn.2019.0029.
7
High intratumoral expression of vimentin predicts histological transformation in patients with follicular lymphoma.波形蛋白在肿瘤内的高表达预示着滤泡性淋巴瘤患者的组织学转化。
Blood Cancer J. 2019 Mar 18;9(4):35. doi: 10.1038/s41408-019-0197-5.
8
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.STAT3 反义寡核苷酸 AZD9150 在经过大量预处理的淋巴瘤患者亚组中的应用：一项 1b 期试验的结果。
J Immunother Cancer. 2018 Nov 16;6(1):119. doi: 10.1186/s40425-018-0436-5.
9
COSMIC: the Catalogue Of Somatic Mutations In Cancer.COSMIC：癌症体细胞突变目录。
Nucleic Acids Res. 2019 Jan 8;47(D1):D941-D947. doi: 10.1093/nar/gky1015.
10
Transcription activated p73-modulated cyclin D1 expression leads to doxorubicin resistance in gastric cancer.转录激活的p73调节的细胞周期蛋白D1表达导致胃癌对多柔比星耐药。
Exp Ther Med. 2018 Feb;15(2):1831-1838. doi: 10.3892/etm.2017.5642. Epub 2017 Dec 15.